Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3562-3568

  Landers, John E ^a   Cassel, Suzanne L ^a   George, Donna L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; PROTEIN P53;

ARTICLE; CHORIOCARCINOMA; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION; TRANSLATION REGULATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, COMPLEMENTARY; GENES, P53; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROTEIN BIOSYNTHESIS; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030795068     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Cahilly-Snyder, L., Yang-Feng, T., Francke, U., and George, D. L. Molecular analysis and chromosome mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol. Genet., 13: 235-244, 1987.
2. Fakharzadeh, S. S., Trusko, S. P., and George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10: 1565-1569, 1991.
3. Finlay, C. A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol., 13: 301-306, 1993.
4. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (Lond.), 358: 80-83, 1992.
5. Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S. C., Huvos, A. G., and Healey, J. H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res., 53: 16-18, 1993.
6. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., and Vogelstein, B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53: 2231-2234, 1993.
7. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E., and Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of malignant gliomas without p53 mutations. Cancer Res., 53: 2736-2739, 1993.
8. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
9. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
10. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (Lond.), 362: 857-860, 1993.
11. Chen, J., Marechal, V., and Levine, A. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13: 4107-4114, 1993.
12. 1 cell cycle arrest. Oncogene, 11: 2445-2449, 1995.
13. Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., and Lunec, J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med., 2: 912-917, 1996.
14. Xiao, Z., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R., and Livingston, D. M. Interaction between the retinoblastoma protein and the Oncoprotein MDM2. Nature (Lond.), 375: 694-698, 1995.
15. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., LaThangue, N. B., and Kouzarides, T. Stimulation of E2F/DP1 transcriptional activity by MDM2 Oncoprotein. Nature (Lond.), 375: 691-694, 1995.
16. Fiddler, T. A., Smith, L., Tapscott, S. J., and Thayer, M. J. Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol. Cell. Biol., 16: 5048-5057, 1996.
17. Landers, J. E., Haines, D. S., Strauss, J. F., III, and George, D. L. Enhanced translation: a novel mechanism of mdm2 overexpression identified in human tumor cells. Oncogene, 9: 2745-2750, 1994.
18. Bodner, S. M., Minna, J. D., Jensen, S. M., D'Amico, D., Carbon, D., Mitsudomi, T., Fedorko, J., Buchhagen, D. L., Nau, M. M., and Gazdar, A. F. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7: 743-749, 1992.
19. Bartek, J., Iggo, R., Cannon, J., and Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893-899, 1990.
20. Casey, G., Lo-Hsueh, M., Lopez, M. E., Vogelstein, B., and Stanbridge, E. J. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene, 6: 1791-1797, 1991.
21. Zhu, L., Heuvel, S. V. D., Helin, K., Fattaey, A., Ewen, M., Livingston, D., Dyson, N., and Harlow, E. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes & Dev., 7: 1111-1125, 1993.
22. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
23. Jiang, H., Lin, J., Su, Z., Herlyn, M., Kerbel, R. S., Weissman, B. E., Welch, D. R., and Fisher, P. B. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase p21, is differentially expressed during growth, differentiation, and progression in human melanoma cells. Oncogene, 10: 1855-1864, 1995.
24. Weiss, J., Schwechheimer, K., Cavenee, W. K., Herlyn, M., and Arden, K. C. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer, 54: 693-699, 1993.
25. Halbert, C. L., Demers, G. W., and Galloway, D. A. The E7 gene of human papillomavirus type 16 is sufficient for immotilization of human epithelial cells. J. Virol., 65: 473-478, 1991.
26. Murphy, M., Pykett, M. J., Harnish, P., Zang, K. D., and George, D. L. Identification and characterization of genes differentially expressed in menigiomas. Cell Growth & Differ., 4: 715-722, 1993.
27. Bártkova, J., Bártek, J., Lukás, J., Vojtesek, B., Stasková, Z., Rejthat, A., Kovarík, J., Midgley, C. A., and Lane, D. P. p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int. J. Cancer, 49: 196-202, 1991.
28. Davidoff, A. M., Pence, J. C., Shorter, N. A., Iglehart, J. D., and Marks, J. R. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene, 7: 127-133, 1992.
29. Rubio, M., von Deimling, A., Yandell, D. W., Wiestler, O. D., Gusella, J. F., and Louis, D. N. Accumulation of wild-type p53 protein in human astrocytomas. Cancer Res., 53: 3465-3467, 1993.
30. Lang, F. K., Miller, D. C., Pishorody, S., Koslow, M., and Newcomb, E. W. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene, 9: 949-954, 1994.
31. Moll, U., LaQuaglia, M., Bénard, J., and Riou, G. Wild-type p53 undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA, 92: 4407-4411, 1995.
32. Riou, G., Barrols, M., Prost, S., Terrier, J. J., Theodore, C., and Levine, A. J. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol. Carcinog., 12: 124-131, 1995.
33. Stretch, J. R., Gatter, K. C., Ralkiaer, E., Lane, D. P., and Harris, A. L. Expression of mutant p53 in melanoma. Cancer Res., 51: 5976-5979, 1991.
34. Lassam, N. J., From, L., and Kahn, H. J. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res., 53: 2235-2238, 1993.
35. Montano, X., Shamsher, M., Whitehead, P., Dawson, K., and Newton, J. Analysis of p53 in cutaneous melanoma cell lines. Oncogene, 9: 1455-1459, 1994.
36. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
37. Barak, Y., Juven, T., Haffner, R., and Oren, M. mdm2 expression is induced by wild type-p53 activity. EMBO J., 12: 461-468, 1993.
38. Otto, A., and Deppert, W. Up-regulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53. Oncogene, 8: 2591-2603, 1993.
39. Juven, T., Barak, Y., Zauberman, A., George, D. L., and Oren, M. Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene, 8: 3411-3416, 1993.
40. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes & Dev., 7: 1126-1132, 1993.
41. Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y., and Oren, M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res., 23: 2584-2592, 1995.
42. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
43. Lechner, M. S., Mack, D. H., Finicle, A. B., Crook, T., Vousden, K. H., and Laimins, L. A. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J., 11: 3045-3052, 1992.
44. Meitz, J. A., Unger, T., Huibregtse, J. M., and Howley, P. M. The transcriptional transactivation function of wild-type p53 is inactivated by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J., 11: 5013-5020, 1992.
45. Barak, Y., Gottleib, E., Juven-Gershon, T., and Oren, M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes & Dev., 8: 1739-1749, 1994.
46. Haines, D. S., Landers, J. E., Engle, L. J., and George, D. L. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol., 14: 1171-1178, 1994.
47. Fenaux, P., Preudhomme, C., Quiquandon, I., Laï, J. L., Pignon, J. M., Loucheux-Lefebvre, M. H., Buters, F., Berger, R., and Kerckaert, J. P. p53 gene mutations in acute myeloid leukemia. J. Haematol., 80: 178-183, 1992.
48. Trecca, D., Longo, L., Biondi, A., Cro, L., Calori, R., Grignani, F., Maiolo, A. T., Pelicci, P. G., and Neri, A. Analysis of p53 gene mutations in acute myeloid leukemia. Am. J. Hematol., 46: 304-309, 1994.
49. Crook, T., Wrede, D., Tidy, J. A., Mason, W. P., Evans, D. J., and Vousden, K. H. Clonal p53 mutation in primary cervical cancer: association with human papillomavirus-negativc tumors. Lancet, 339: 1070-1073, 1992.
50. Scheffner, M., Münger, K., Byrne, J. C., and Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.
51. Fu, L., Minden, M. D., and Benchimol, S. Translational regulation of p53 gene expression. EMBO J., 15: 4392-4401, 1996.
52. Lutzger, S. G., and Levine, A. J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat. Med., 2: 804-810, 1996.
53. Gelsleichter, L., Gown, A. W., Zarbo, R. J., Wang, H., and Coltrera, M. D. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod. Pathol., 8: 530-535, 1995.
54. Lianes, P., Orlow, I., Zhang, Z-F., Oliva, M. R., Sarkis, A. S., Reuter, V. E., and Cordon-Cardo, C. Altered patterns of MDM2 and PT53 expression in human bladder cancer. J. Natl. Cancer Inst., 86: 1325-1330, 1994.
55. Picksley, S. M., Spicer, J. F., Barnes, D. M., and Lane, D. P. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Acta Oncol., 35: 429-434, 1996.